Company intelligence / Profile preview

Andicon

Ownership: Private
Development stage: Other

Overview

Andicon is a biotechnology company focused on the development of novel therapeutics for the treatment of prostate cancer. The company's primary research centers on targeting the androgen receptor, a key driver in the progression of the disease. By developing small molecule inhibitors, Andicon aims to provide more effective treatment options for patients with advanced or resistant forms of prostate cancer. The company is currently in the pre-clinical stage of development, working to validate its lead candidates and advance them toward clinical trials.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Andicon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Andicon.

Explore the full profile